VIRTUAL KOL EVENT

The Potential Role of Anti-OX40/OX40L Monoclonal Antibodies (mAbs) in the Treatment of Alopecia Areata (AA)

Wednesday, May 28th, 2025 | 11:00AM ET

Designed to be different:

Developing a potential best-in-class anti-OX40 treatment with features that matter to patients

ImageneBio is a clinical-stage biotechnology company developing therapeutics for patients who have immunological, autoimmune and inflammatory diseases. IMG-007 is our next-generation investigational anti-OX40 monoclonal antibody.

background patient image
background patient image

IMG-007

IMG-007 is an extended half-life anti-OX40 monoclonal antibody in clinical development that targets and inhibits OX40 receptor signaling without depleting T cells for potential enhanced efficacy, safety, and patient convenience.

News

November 12, 2025

ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team

read more »

November 06, 2025

ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences

read more »

August 01, 2025

ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

read more »
Scroll to Top
Secret Link